Gilead Sciences: Hold Rating Maintained Amid Near-Term Challenges and Limited Growth Prospects
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences Agrees to Pay $202 Million to Settle Claims of Kickbacks to Doctors for HIV Drug Prescriptions
Express News | U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors
CIBC Introducing Additional U.S. Canadian Depositary Receipts
Gilead To Present New Research To EASL Congress
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV's Impact in the United States
Investors in Gilead Sciences (NASDAQ:GILD) Have Seen Favorable Returns of 98% Over the Past Three Years
BofA Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $126
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating
Gilead Sciences Inc. Stock Climbs 3.1%, Outperforms Competitors
SA Analyst Downgrades: TSLA, AAPL, T, PG, HPE, GILD, LRCX, ARCC
HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating
Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Edwards Lifesciences (EW) and Gilead Sciences (GILD)
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Gilead Sciences: Strong Market Position and Positive Long-Term Outlook Justify Buy Rating
Express News | Gilead : HSBC Raises Target Price to $93 From $82
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street
Gilead Sciences First Quarter 2025 Earnings: Misses Expectations
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125